Skip to main content Skip to main content
Go to homepage

ASP0367 in patients with primary mitochondrial myopathy

Safety and efficacy of ASP0367 in patients with primary mitochondrial myopathy


See complete study details here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Astellas Pharma, Inc.

Full IRB Study Title:
A Randomized, Double-blind, Placebo-controlled Adaptive Phase 2/3 Study with Open-label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants with Primary Mitochondrial Myopathy
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Hilary Tonni,, 330-543-3193

Lead Investigator
Bruce H. Cohen, MD, FAAN

Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.